Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.75 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975550 | 1.00 | NNMT (1.00) | NNMTMKNK1MKNK2SMN1; SMN2SIRT6 | |
| Hydrochloric Acid SCHEMBL5013391 | 0.98 | NNMT (0.96) | NNMTMKNK1MKNK2SMN1; SMN2SIRT6 | |
| Hydrochloric Acid SCHEMBL6234386 | 0.98 | NNMT (0.96) | NNMTMKNK1MKNK2SMN1; SMN2SIRT6 | |
| SCHEMBL5013528 | 0.92 | NNMT (0.84) | NNMTMKNK1MKNK2SMN1; SMN2SIRT6 | |
| SCHEMBL18228074 | 0.84 | NNMT (0.72) | NNMTMKNK1MKNK2SMN1; SMN2SIRT6 | |
| SCHEMBL1515510 | 0.84 | NNMT (0.72) | NNMTMKNK1MKNK2SMN1; SMN2SIRT6 | |
| SCHEMBL26034355 | 0.83 | NNMT (0.68) | NNMTMKNK1MKNK2SMN1; SMN2MAPT | |
| SCHEMBL29757598 | 0.82 | NNMT (0.70) | NNMTMKNK1MKNK2SIRT6CA1 | |
| SCHEMBL29514668 | 0.82 | NNMT (0.70) | NNMTMKNK1MKNK2SMN1; SMN2SIRT6 | |
| SCHEMBL185291 | 0.82 | NNMT (0.70) | NNMTMKNK1MKNK2SIRT6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118755829-A | Application of NNMT as treatment target of sunitinib resistance of renal cell carcinoma and NNMT inhibitor | 华中科技大学同济医学院附属协和医院 | 2024-10-11 | — | — | CN | claimed |
| CN-116375549-A | Method and system for synthesizing amide compound from nitrile compound | 深圳湾实验室 | 2023-07-04 | — | — | CN | claimed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| CN-110914257-B | Spiroheptylhydantoins as ROCK inhibitors | 百时美施贵宝公司 | 2023-05-26 | — | — | CN | claimed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | claimed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | claimed |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-10-25 | — | — | US | claimed |
| WO-2022106579-A1 | COMPOUNDS FOR TREATING A DISEASE ASSOCIATED WITH MACROPHAGE SENESCENCE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-05-27 | — | — | WO | claimed |
| EP-3980425-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS InnoPharm (Shanghai) Ltd. (CN) | 2022-04-13 | — | — | EP | claimed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | claimed |
| EP-1560589-A1 | NOVEL COMPLEXES OF FATTY ACID ESTERS OF POLYHYDROXYALKANES AND PYRIDINE CARBOXY DERIVATIVES | Astion Dermatology A/S (DK) | 2005-08-10 | — | — | EP | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | claimed |
| WO-2004014365-A1 | PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| WO-2004000333-A1 | NOVEL COMPLEXES OF FATTY ACID ESTERS OF POLYHYDROXYALKANES AND PYRIDINE CARBOXY DERIVATIVES | ASTION DERMATOLOGY A/S (DK) | 2003-12-31 | — | — | WO | claimed |
| EP-1362054-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, SSTR3 | NNMT 2914/4885MKNK1 2783/4885MKNK2 2882/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | NNMT 3350/4885MKNK1 408/4885MKNK2 430/4885 |
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | NNMT 4088/4885MKNK1 2487/4885MKNK2 2801/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | NNMT 2414/4885MKNK1 3042/4885MKNK2 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.